Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hypoxemic Human Metapneumovirus Pneumonia in a Young Immunocompetent Man in the First Autumn After the Reclassification of Coronavirus Disease.
Cureus
December 2024
Department of Internal Medicine, Hiroshima City Funairi Citizens Hospital, Hiroshima, JPN.
Although human metapneumovirus(hMPV) infection can induce severe symptoms in older adults or immunocompromised patients, it usually causes mild symptoms in young immunocompetent adults. The prevalence of hMPV infectious disease is highest during the late winter and early summer. We report a hypoxemic case of hMPV infection in a young immunocompetent man that occurred in the first autumn after the reclassification of coronavirus disease (COVID-19) from Class 2 to Class 5.
View Article and Find Full Text PDFThiazide-Associated Hyponatremia and Mortality Risk: A Cohort Study.
Kidney Med
February 2025
Department of Internal Medicine, Research Methodology and Biostatistics Core, Office of Research, Morsani College of Medicine, University of South Florida Health, Tampa, FL.
Rationale & Objective: There are likely over 42 million patients with hypertension taking thiazides in the United States and many more worldwide. Hyponatremia is a common complication of thiazide therapy. It is not currently known if thiazide-associated hyponatremia is also associated with increased mortality.
View Article and Find Full Text PDFLetter by Xing et al Regarding Article, "Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure".
Circ Heart Fail
January 2025
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, China. (H.X., C.D., H.Z.).
Response by Aronson et al to Letter Regarding Article, "Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure".
Circ Heart Fail
January 2025
Division of Cardiovascular Medicine, The Ohio State University, Columbus (W.T.A.).
Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure for Clinical Phenotypes.
Circ Cardiovasc Qual Outcomes
January 2025
Tokyo Cardiovascular Care Unit Network Scientific Committee, Japan (Y.S., N.N., S. Kohsaka, K.H., T.K., M. Takei, T.J., H.N., J.M., A.S., D.K., S.T., S. Koba, T.Y., M. Takayama).
Background: The absence of practice standards in vasoactive agent usage for acute decompensated heart failure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed to assess temporal trends and institutional differences in vasodilator and inotrope/vasopressor utilization among patients with acute decompensated heart failure, considering their clinical phenotypes.
Methods: Data were extracted from a government-funded multicenter registry covering the Tokyo metropolitan area, comprising consecutive patients hospitalized in intensive/cardiovascular care units with a primary diagnosis of acute decompensated heart failure between January 2013 and December 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!